8 completed, 3 unknown, 2 not yet recruiting, 1 terminated. 9 Not applicable, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 9 | Completed 4, Unknown 3, Not yet recruiting 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow pycnogenols: new trials by email Literature Review of pycnogenols trials Research Report on pycnogenols
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pycnogenol (French Maritime Pine Bark) for the Treatment of Gulf War Illness Placebo, Pycnogenol, 100mg, Pycnogenol, 200mg - Gulf War Syndrome | Not applicable | Not yet recruiting | University of Alabama at Birmingham | 20 | 2026-11-01 | 2026-09-21 |
| The Improving Effects of French Maritime Pine Bark Extract on Antioxidation and Anti-inflammation a in Post-menopausal Women Based on Nutrigenomic Approach French maritime pine bark extract, Placebo - Gene Expression, Nutrigenomics | Not applicable | Not yet recruiting | Taipei Medical University | 46 | 2026-09-07 | 2026-10-02 |
| Pycnogenol® in Post-COVID-19 Condition Pycnogenol®, Placebo - Post COVID-19 Condition, Long COVID | Phase 3 | Completed | University of Zurich | 153 | 2023-06-07 | 2026-04-29 |
| Impact of Pycnogenol® on Gingival Inflammation Pycnogenol, Placebo - Periodontitis | Not applicable | Completed | Wuerzburg University Hospital | 90 | 2022-03-17 | 2024-08-09 |
| Improving Effects of Fish Oil Combined With Pine Bark Extract on Cognitive Decline FOPE (fish oil + pine extract), FO (fish oil +placebo) - Mild Cognitive Impairment | Not applicable | Unknown | Taipei Medical University | 60 | 2021-11-11 | 2022-10-10 |
| Mirtogenol and Bimatoprost on IOP in Hispanics With Open-Angle Glaucoma Experimental: Oral Mirtogenol, Placebo of oral Dietary supplement - Glaucoma | Not applicable | Unknown | University of Puerto Rico | 72 | 2020-05-15 | 2020-05-08 |
| The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments 50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC - Climacteric; Menorrhagia, Menopausal, Menopause | Not applicable | Unknown | Legacy Health System | 40 | 2018-10-01 | 2018-10-12 |
| Effect of Pycnogenol® on ADHD Pycnogenol, Methylphenidate, Placebo - ADHD | Phase 3 | Completed | Nina Hermans | 88 | 2017-09-01 | 2021-04-28 |
| Effects of Botanical Microglia Modulators in Gulf War Illness Boswellia Serrata, Curcumin, Epimedium - Gulf War Illness | Not applicable | Completed | University of Alabama at Birmingham | 36 | 2016-07-01 | 2025-01-24 |
| Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects Pycnogenol, Placebo - Cardiac Fibrosis, Diastolic Dysfunction | Phase 2 | Terminated | University of Arizona | 9 | 2009-07-01 | 2013-12-17 |
| Pycnogenol and Endothelial Function in Coronary Artery Disease Pycnogenol, Placebo - Coronary Artery Disease | Not applicable | Completed | University of Zurich | 25 | 2008-03-01 | 2010-02-10 |
| Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study Pine Bark Extract (Flavangenol®) - Hypertension | Not applicable | Completed | Stanford University | 130 | 2006-10-01 | 2014-04-02 |
| Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors Pycnogenol - Lymphedema, Breast | Phase 2 | Completed | National Center for Complementary and Integrative Health (NCCIH) | 26 | 2003-08-01 | 2008-04-22 |
| Pycnogenol for the Treatment of Lymphedema Pycnogenol, Placebo - Lymphedema | Phase 2 | Completed | University of Wisconsin, Madison | 2 | 2002-05-01 | 2015-10-05 |
Hypertension (2) · Lymphedema (2) · Persian Gulf Syndrome (2) · Attention Deficit Disorder with Hyperactivity (1) · COVID-19 (1) · Cognitive Dysfunction (1) · Coronary Artery Disease (1) · Glaucoma (1) · Menorrhagia (1) · Neoplasms (1) · Periodontitis (1) · Post-Acute COVID-19 Syndrome (1)
Taipei Medical University (2) · University of Alabama at Birmingham (2) · University of Zurich (2) · Legacy Health System (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · Nina Hermans (1) · Stanford University (1) · University of Arizona (1) · University of Puerto Rico (1) · University of Wisconsin, Madison (1) · Wuerzburg University Hospital (1)
United States (7) · Switzerland (2) · Belgium (1) · Germany (1) · Puerto Rico (1) · Taiwan (1)
Alexia Anagnostopoulos, MD (1) · Georg Noll, MD (1) · Jahn S Fehr, Prof., MD (1) · James F. Cleary, M.B.B.S. (1) · Jarred W Younger, PhD (1) · Jarred Younger, PhD (1) · Jorge R Miranda, Pham.D. (1) · Nina Hermans, PhD (1) · Paul R Hutson, PharmD (1) · Randall S. Stafford MD, PhD (1) · Reza Antoszewska, NP-C (1) · Ronald R Watson, PhD (1)
PMID 12751655, PMID 16488940, PMID 18618008, PMID 20876405, PMID 22240497, PMID 23316132, PMID 28351412, PMID 33802272, PMID 33802381, PMID 33915962, PMID 38879571, PMID 40362854, PMID 42118816, PMID 42790915